RGX-202 demonstrated significant functional improvements in DMD patients, surpassing natural history controls in key assessments like the North Star Ambulatory Assessment. High microdystrophin ...
Recently, additional findings from the ongoing phase 1/2 AFFINITY DUCHENNE trial (NCT05693142) of RGX-202 (REGENXBIO), an investigational adeno-associated virus (AAV) vector-based gene therapy for ...
Curran Simpson, President and CEO, highlighted strong late-stage clinical progress and the company's positioning for multiple gene therapy launches, stating the business is “in-store for an exciting ...
The last time I wrote about REGENXBIO Inc. (RGNX) it was in a Seeking Alpha article entitled "Regenxbio: DMD Program Lends Additional Credibility to NAV Technology platform." At the time, I spoke ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results